All News
Filter News
Found 809,065 articles
-
New England Journal of Medicine Publishes Results of Global Phase 3 Clinical Program of Vadadustat for the Treatment of Anemia Due to Chronic Kidney Disease
4/28/2021
Akebia Therapeutics, Inc. (Nasdaq: AKBA), a biopharmaceutical company with the purpose to better the lives of people impacted by kidney disease, today announced that the New England Journal of Medicine (NEJM) has published the results of the global Phase 3 clinical program of vadadustat for the treatment of anemia due to chronic kidney disease (CKD) in adult patients on dialysis
-
Sharps Compliance Reports Fiscal 2021 Third Quarter Results
4/28/2021
Sharps Compliance Corp., a leading full-service national provider of comprehensive waste management solutions including medical, pharmaceutical and hazardous, reported financial results for the third quarter ended March 31, 2021.
-
Adverum Biotechnologies Provides Update on the INFINITY Trial Evaluating ADVM-022 in Patients with Diabetic Macular Edema
4/28/2021
Adverum Biotechnologies, Inc. (Nasdaq: ADVM) announced a Suspected Unexpected Serious Adverse Reaction (SUSAR) of hypotony (clinically-relevant decrease in ocular pressure) in its INFINITY clinical trial evaluating ADVM-022 gene therapy for the treatment of diabetic macular edema (DME)
-
Samsung Biologics Reports First Quarter 2021 Financial Results
4/28/2021
Samsung Biologics, the world's leading contract development and manufacturing organization, announced financial results for the first quarter of fiscal 2021.
-
Alcon to Acquire U.S. Commercialization Rights to Ophthalmic Eye Drop Simbrinza
4/28/2021
Alcon (SIX/NYSE: ALC), the global leader in eye care dedicated to helping people see brilliantly, today announced it has signed an agreement to acquire exclusive U.S. commercialization rights to Simbrinza®(brinzolamide/brimonidine tartrate ophthalmic suspension) 1%/0.2% from Novartis.
-
ClearPoint Neuro, Inc. Congratulates Voyager Therapeutics on FDA Clearance of IND Application for Gene Therapy Candidate VY-HTT01 for Treatment of Huntington’s Disease
4/28/2021
ClearPoint Neuro, Inc. (Nasdaq: CLPT) (the “Company”), a global therapy-enabling platform company providing navigation and delivery to the brain, today congratulates Voyager Therapeutics on receiving FDA clearance of the IND application for their gene therapy candidate VY-HTT01 for the treatment of Huntington’s disease.
-
MyoStrain®, MyoStress™ Rapid Hyperventilation Breath-hold Maneuver Enables First-of-its-Kind Needle-Free Stress Protocol for the Accurate Detection of Myocardial Ischemia
4/28/2021
A new peer-reviewed study accepted in the Journal of the American College of Cardiology: Cardiovascular Imaging validated Myocardial Solutions ("MSI") technologies MyoStrain and MyoStress in a new stress testing protocol utilizing a hyperventilation breath-hold (HVBH) maneuver to accurately detect myocardial ischemia
-
XPhyto Pursues Market Access in Israel for its COVID-19 PCR Rapid Test
4/28/2021
XPhyto Therapeutics Corp. is pleased to announce that it has delivered 2,000 of its rapid 25-minute PCR tests to an established medical distributor in Israel for clinical evaluation of Covid-ID Lab for the purpose of commercial regulatory approval and potential product distribution.
-
Depression Disconnect: GeneSight® Mental Health Monitor Shows Misunderstanding of Depression and TreatmentNew poll shows 83% of people with depression agree life would be easier if others could understand their depression
4/28/2021
In a new nationwide poll, the GeneSight® Mental Health Monitor found that 83% of people with depression agree that life would be easier if others could understand their depression.
-
Canon Medical Expands AI-Based Image Reconstruction Technology to Body Applications on Galan 3T MR System
4/28/2021
Canon Medical is bringing the power of accessible artificial intelligence (AI) for improved image quality to more patients with expanded clinical indications for 3T MR
-
BioVie to Present at 2021 B. Riley Securities’ Neuroscience Conference
4/28/2021
BioVie Inc., a clinical-stage company developing innovative drug therapies for the treatment of liver disease and, pending closing of the announced transaction with NeurMedix, neurological and neuro-degenerative disorders and certain cancers, announced the participation of its President and Chief Executive Officer Cuong Do at the 2021 B. Riley Securities’ Neuroscience Conference.
-
Adcentrx Therapeutics Announces Completion of $50m Series A Financing Led By CBC Group To Accelerate Next-Generation Conjugate Drugs Research & Development
4/28/2021
Adcentrx Therapeutics ("Adcentrx"), a biotechnology company focused on accelerating breakthroughs in antibody drug conjugate ("ADC") therapeutic development, announced the closing of $50m Series A financing to power the development of next generation ADC for improving patient treatment options.
-
Orchard Therapeutics Announces Multiple Presentations at the 24th Annual Meeting of the American Society of Gene & Cell Therapy
4/28/2021
Seven abstracts accepted show the potential of HSC gene therapy to transform the treatment of multiple severe rare disorders
-
Biogen Provides Regulatory Update on the Supplemental Biologic License Application (sBLA) for Subcutaneous Administration of TYSABRI® (natalizumab)
4/28/2021
Biogen Inc. (Nasdaq: BIIB) today announced that it has received a Complete Response Letter (CRL) from the U.S. Food and Drug Administration (FDA) for its supplemental Biologic License Application (sBLA) for a new subcutaneous (SC) route of administration of TYSABRI® (natalizumab) to treat relapsing multiple sclerosis (MS).
-
Aldeyra Therapeutics, Inc. Announces Pricing of $125 Million Public Offering of Common Stock
4/28/2021
Aldeyra Therapeutics, Inc. (Nasdaq: ALDX) (Aldeyra), a clinical-stage biotechnology company focused on the development of novel therapies with the potential to improve the lives of patients with immune-mediated diseases, today announced the pricing of an underwritten public offering of 10,000,000 shares of its common stock at a public offering price of $12.50 per share
-
Antengene Announces XPO1 Inhibitor Selinexor Prescribed for the First Time in the Pilot Zone of Hainan Province and Authorized to be Expanded Beyond the Pilot Zone for Outpatient Treatment
4/28/2021
With the official release and implementation of the Overall Plan for the Construction of Hainan Free Trade Port, patient can now access global innovative medicines in mainland China
-
FibroGen to Present at Upcoming Investor Conference - Apr 28, 2021
4/28/2021
FibroGen, Inc. announced that Enrique Conterno, Chief Executive Officer, will participate in a fireside chat at the BofA Securities 2021 Virtual Health Care Conference on May 13, 2021 at 5:00 PM Eastern Time.
-
Enalare Therapeutics Announces Partnership With BARDA to Advance Development of Its Lead Product ENA-001
4/28/2021
Enalare Therapeutics Inc. announced today that it has received an initial contract from the Biomedical Advanced Research and Development Authority (BARDA), part of the Office of the Assistant Secretary for Preparedness and Response at the U.S. Department of Health and Human Services, to support development of the company's lead product ENA-001.
-
Innovent Announces First Patient Dosed in the Phase 2 Clinical Trial of IBI302, a First-in-class Ophthalmic Anti-VEGF and Anti-Complement Bispecific Fusion Protein for Neovascular Age-Related Macular Degeneration
4/28/2021
Innovent Biologics, Inc. ("Innovent") (HKEX: 01801), a world-class biopharmaceutical company that develops, manufactures and commercializes high quality medicines for the treatment of oncology, metabolic, autoimmune, ophthalmology and other major diseases, announces that the first patient has been successfully dosed in a Phase 2 clinical trial for IBI302,
-
Results from Calithera Biosciences’ CANTATA Study to Be Presented at 2021 ASCO Annual Meeting
4/28/2021
Calithera Biosciences, Inc., a clinical-stage biotechnology company focused on discovering and developing novel small-molecule drugs for the treatment of cancer and other life-threatening diseases, announced that final results from the CANTATA clinical study will be shared in an oral presentation at the American Society of Clinical Oncology 2021 Annual Meeting taking place virtually June 4-8, 2021.